Mentioned in ?
References in periodicals archive ?
ANI") (NASDAQ: ANIP) today announced the launch of Propafenone Hydrochloride 150mg, 225mg and 300mg oral tablets, indicated for use in the treatment of various arrhythmias.
Propafenone Hydrochloride is also indicated to treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life threatening.
The 150 mg Propafenone Hydrochloride Tablets is a white, scored round film coated tablet with "ETH" on one side and "331" with a bisect on the reverse.
NYSE: WPI) announced today that the Food and Drug Administration (FDA) has approved Watson's abbreviated new drug application (ANDA) for Propafenone Hydrochloride Tablets, 150 mg and 225 mg.